Active Filter(s):
Details:
MBRC-101 (monomethyl auristatin E)is a novel, targeted ADC which targets the EphA5 receptor tyrosine kinase. It is under phase 1 clinical development for the treatment of multiple solid tumor cancers, including breast, non-small cell lung and other solid tumors.
Lead Product(s): Monomethyl Auristatin E
Therapeutic Area: Oncology Product Name: MBRC-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023